Endevica Bio Spins Off Abisati to Pursue Weight Loss Solutions
The newly created company, Abisati, is set to focus on developing 710GO, an innovative oral MC4R agonist drug that has demonstrated efficacy in nonhuman primates and rats.
Mission and Objectives of Abisati
While Endevica Bio specializes in pioneering peptide drug candidates, the spin-off, Abisati, aims to harness the potential of 710GO as a weight loss treatment. Abisati is gearing up for a phase 1 trial scheduled for the latter half of the year 2025, demonstrating the commitment to bringing this significant treatment to market.
Understanding 710GO's Mechanism
710GO works by leveraging the melanocortin system, which plays a crucial role in regulating appetite and energy expenditure. Endevica Bio's results indicate that this peptide not only promotes weight loss but does so while maintaining safety, as seen in studies conducted with obese monkeys and rats.
Promising Results from Animal Studies
In trials with obese monkeys, the drug led to an impressive 7.5% average weight loss over one month compared to control groups. Additionally, a notable decrease of around 20% in daily caloric intake was observed. Such outcomes are especially favorable when compared to GLP1s, which are known for causing rapid appetite reduction followed by rebound eating patterns.
Endevica Bio's Continued Research and Development
Endevica Bio remains a leader in researching the central melanocortin system for various other medical indications beyond weight loss. This includes studying treatments for cachexia, a syndrome leading to severe weight loss in chronic illnesses like cancer. The ongoing research establishes the importance of targeted drug development in metabolic disorders.
Insights from Leadership
Russell Potterfield, CEO and Executive Chairman of both Endevica Bio and Abisati, expressed optimism about the potential for 710GO to transform the lives of those battling obesity. He emphasized the prospect of offering a drug that could help achieve weight loss without the conventional side effects, such as nausea, often found with existing medications.
A New Approach to Weight Management
Dr. Daniel Marks, Co-Author and Chief Medical and Scientific Officer at Endevica Bio and Abisati, highlighted that the journey to understanding weight regulation disorders has been extensive. He stated that millions dealing with obesity or involuntary weight loss face challenges that are fundamentally linked to brain function rather than lifestyle choices alone. This knowledge drives the development of their drugs, targeting brain systems to restore healthy weight regulation.
Conclusion: Hope for Weight Loss Treatments
The inception of Abisati marks a strategic endeavor to advance the development of 710GO, an exciting step toward providing effective solutions for weight management. Through the combined expertise of Endevica Bio and Abisati, there lies a significant opportunity to address the critical and growing issues associated with obesity.
Frequently Asked Questions
What is 710GO?
710GO is an oral MC4R agonist that has shown efficacy in promoting weight loss in animal studies.
What is the goal of Abisati?
Abisati aims to develop and bring to market 710GO as an effective weight loss treatment.
Who is leading Abisati?
Russell Potterfield serves as the CEO and Executive Chairman of Abisati.
What kind of studies have been conducted on 710GO?
Animal studies involving obese monkeys and rats have shown significant weight loss and changes in caloric intake.
What is Endevica Bio's focus moving forward?
Endevica Bio will continue to research new drug candidates across various medical conditions, including metabolic disorders and cancer-related cachexia.
